PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The firm's portfolio includes Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PTC Therapeutics reports robust earnings, faces data release delays

PTC Therapeutics demonstrated strong financial performance and revenue growth in Q4 2022, setting a positive trajectory for 2023.
While facing challenges such as data release delays and regulatory engagements, the company's innovative pipeline and commercial successes position it well for future opportunities.
With upcoming data readouts, regulatory discussions, and market expansion initiatives, PTC is poised to navigate challenges and leverage opportunities for continued growth and impact.

PTC Therapeutics achieves record revenue, faces regulatory challenges and growth opportunities

PTC Therapeutics reported strong financial performance in Q1 2023, with a clear path towards achieving revenue targets. While facing challenges such as regulatory interactions and data expectations, the company is leveraging opportunities in upcoming study results and strategic initiatives to drive growth and market differentiation.

PTC Therapeutics reports strong Q2 revenue and advances pipeline

PTC Therapeutics showcased robust financial performance, positive trial outcomes, and strategic cost-saving measures in Q2 2023.
The company's strong revenue growth, global expansion plans, and pipeline advancements position it for sustained success.
Challenges include addressing analyst inquiries, navigating regulatory pathways, and ensuring market access post-2024.
Opportunities in product launches, regulatory activities, and strategic partnerships offer avenues for continued growth and innovation.

PTC Therapeutics reports robust Q3 earnings and strategic growth plans

PTC Therapeutics demonstrated strong financial performance and strategic partnerships in Q3 2023 earnings call.
The company's focus on pipeline advancement, commercial growth, and regulatory strategies positions it for future success.
While facing challenges in regulatory compliance and product comparability, PTC Therapeutics is leveraging opportunities for revenue growth and market expansion.

PTC Therapeutics posts robust Q4 earnings amidst regulatory challenges

PTC Therapeutics delivered strong financial performance in Q4 2023, driven by revenue growth and transformative gene therapy results, despite challenges from the CHMP opinion.
The company's strengths lie in its solid balance sheet, positive community feedback, and FDA alignment on registration programs, positioning it for future growth and approvals.
Opportunities abound in the launch of sepiapterin, accelerated approval discussions with the FDA, and promising programs for FA and ALS, signaling a positive outlook for PTC.

PTC Therapeutics reports robust Q1 performance amidst regulatory milestones

PTC Therapeutics demonstrated strong financial and operational performance in Q1 2024, driven by revenue growth and regulatory progress.
While facing challenges such as delays in European market access and regulatory complexities, the company remains focused on key therapeutic advancements.
Opportunities lie in upcoming clinical results, potential market expansions, and strategic regulatory pathways for accelerated product approvals.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

SOUTH PLAINFIELD, N.J., Jan. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its R&D pipeline and commercial progress at the 39th Annual J.P. Morgan Healthcare Conference today, Monday, Jan. 11 at 7:30 a.m. EST. Stuart W. Peltz, Ph.D., Chief...

PTC Therapeutics Provides Update on R&D Pipeline and Commercial Progress at 39th Annual J.P. Morgan Healthcare Conference

SOUTH PLAINFIELD, N.J., Dec. 4, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been granted marketing approval in the Russian Federation for nonsense mutation Duchenne muscular dystrophy (nmDMD). It is estimated that 13% of DMD...

PTC Announces Translarna™ Approval in Russia for the Treatment of Duchenne Muscular Dystrophy

SOUTH PLAINFIELD, N.J., Nov. 19, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1st at 11:45 a.m. ET. The presentation will be webcast live on...

PTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference

PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q3 2020 Results - Earnings Call Transcript

SOUTH PLAINFIELD, N.J., Oct. 29, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced financial results for the third quarter ending September 30, 2020 and provided a corporate update. "I am very pleased by the rapid progress that we have made this quarter with the...

PTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for

SOUTH PLAINFIELD, N.J., Oct. 21, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi™ (risdiplam) was approved in Brazil by the National Health Surveillance Agency (ANVISA) for the treatment of spinal muscular atrophy (SMA). The approval was obtained...

Evrysdi™ (risdiplam) Continues to Make Global Progress for the Treatment of Spinal Muscular Atrophy

ClearPoint Neuro: Becoming The World's Pre-Eminent Neurosurgery Platform

SOUTH PLAINFIELD, N.J., Sept. 28, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that two-year data from Part 1 of the FIREFISH study demonstrated that infants on Evrysdi™ (risdiplam) continued to improve and achieve motor milestones. Evrysdi™ was approved in...

Two-Year Data of Evrysdi™ (risdiplam) in Infants with Spinal Muscular Atrophy Demonstrate Continued Improvement of Developmental Milestones

PTC Therapeutics (PTCT) gets first commercial milestone payment from Roche for first commercial sale of Evrysdi in the United States.

PTC Therapeutics Gets First Milestone Payment for SMA Drug

PTC Therapeutics??? (PTCT) MAA for Evrysdi is accepted by the European Medicines Agency for the treatment of spinal muscular atrophy.

PTC Therapeutics' Application for SMA Drug Accepted by EU

PTC Therapeutics hit a milestone in Europe for its drug to treat the rare genetic disease spinal muscular atrophy, triggering a payment from partner Roche and sending PTCT stock rising.

This Biotech Just Got A Key European Nod To Treat Rare Genetic Disease

PTC Therapeutics Looks Like A Better Value After Recent Pullback

Roche Holding AG

Roche and PTC Therapeutics will challenge Novartis and Biogen with competitive pricing for Evrysdi.

FDA Approves First Oral Treatment for Spinal Muscular Atrophy

SOUTH PLAINFIELD, N.J., Aug. 7, 2020 /PRNewswire/ -- PTC Therapeutics, Inc.

PTC Therapeutics Announces FDA Approval of Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy in Adults and Children 2 months and older

PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q2 2020 Results - Earnings Call Transcript

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -105.43% and -5.24%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Reports Q2 Loss, Lags Revenue Estimates

SOUTH PLAINFIELD, N.J., July 22, 2020 /PRNewswire/ -- PTC Therapeutics, Inc.

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2020 Financial Results

SOUTH PLAINFIELD, N.J., July 20, 2020 /PRNewswire/ -- PTC Therapeutics, Inc.

PTC Therapeutics Announces Agreement to Monetize a Portion of the Risdiplam Royalty Stream for $650 Million

SOUTH PLAINFIELD, N.J., June 29, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended by a majority of votes to remove the statement "efficacy has...

PTC Therapeutics Announces CHMP Recommendation of Translarna™ (ataluren) Label Update for Non-Ambulatory Patients with Duchenne Muscular Dystrophy

Investors have either become overwhelmed by the number of companies entering the quest to address Covid-19 or are having difficulty separating the wheat from the chaff.

PTC Announcement on Covid-19 Candidate Met With Investor Indifference

PTC Therapeutics (PTCT) gets an FDA sanction to begin a phase II/III study on its DHODH inhibitor PTC299 as a potential treatment of COVID-19. The study will start in the United States shortly.

PTC Therapeutics to Commence Phase II/III Coronavirus Study in US

PTC (PTCT) commences a phase II/III study to evaluate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19.

PTC Therapeutics Initiates Phase II/III Study for Coronavirus

SOUTH PLAINFIELD, N.J., June 17, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the U.S. Food and Drug Administration has authorized the initiation of a Phase 2/3 trial to investigate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a...

PTC Therapeutics Announces the Initiation of a Phase 2/3 Clinical Trial to Evaluate PTC299 for the Treatment of COVID-19

SOUTH PLAINFIELD, N.J., June 12, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced two-year data from Part 1 of the SUNFISH trial in children and adults with type 2 or 3 spinal muscular atrophy (SMA) and new preliminary 12-month data from JEWELFISH. The results of...

PTC Therapeutics Announces 2-year Data from Part 1 of SUNFISH and New Data from JEWELFISH Trials for Risdiplam in Patients with Spinal Muscular Atrophy

News for PTC Therapeutics Stock (PTCT)